REFERENCES
1. Varki A. Nothing in glycobiology makes sense, except in the light of evolution. Cell. 2006;126:841-5.
2. Määttänen P, Gehring K, Bergeron JJ, Thomas DY. Protein quality control in the ER: the recognition of misfolded proteins. Semin Cell Dev Biol. 2010;21:500-11.
3. Reily C, Stewart TJ, Renfrow MB, Novak J. Glycosylation in health and disease. Nat Rev Nephrol. 2019;15:346-66.
4. Xu Y, Uddin N, Wagner GK. Chapter Nine - Covalent probes for carbohydrate-active enzymes: from glycosidases to glycosyltransferases. Methods Enzymol. 2018;598:237-65.
7. Bangarh R, Khatana C, Kaur S, et al. Aberrant protein glycosylation: implications on diagnosis and Immunotherapy. Biotechnol Adv. 2023;66:108149.
8. Purushothaman A, Mohajeri M, Lele TP. The role of glycans in the mechanobiology of cancer. J Biol Chem. 2023;299:102935.
9. La Rosa SL, Ostrowski MP, Vera-Ponce de León A, et al. Glycan processing in gut microbiomes. Curr Opin Microbiol. 2022;67:102143.
10. Verhelst X, Dias AM, Colombel JF, et al. Protein glycosylation as a diagnostic and prognostic marker of chronic inflammatory gastrointestinal and liver diseases. Gastroenterology. 2020;158:95-110.
11. Silva MC, Fernandes Â, Oliveira M, et al. Glycans as immune checkpoints: removal of branched N-glycans enhances immune recognition preventing cancer progression. Cancer Immunol Res. 2020;8:1407-25.
12. Xu X, Peng Q, Jiang X, et al. Altered glycosylation in cancer: molecular functions and therapeutic potential. Cancer Commun. 2024;44:1316-36.
13. Fernandes A, Azevedo CM, Silva MC, et al. Glycans as shapers of tumour microenvironment: a sweet driver of T-cell-mediated anti-tumour immune response. Immunology. 2023;168:217-32.
14. Crocker PR, Gordon S. Properties and distribution of a lectin-like hemagglutinin differentially expressed by murine stromal tissue macrophages. J Exp Med. 1986;164:1862-5.
15. Angata T, Tabuchi Y, Nakamura K, Nakamura M. Siglec-15: an immune system Siglec conserved throughout vertebrate evolution. Glycobiology. 2007;17:838-6.
16. Lehmann F, Gäthje H, Kelm S, Dietz F. Evolution of sialic acid-binding proteins: Molecular cloning and expression of fish siglec-4. Glycobiology. 2004;14:959-8.
17. Angata T, Margulies EH, Green ED, Varki A. Large-scale sequencing of the CD33-related Siglec gene cluster in five mammalian species reveals rapid evolution by multiple mechanisms. Proc Natl Acad Sci USA. 2004;101:13251-6.
18. Duan S, Paulson JC. Siglecs as immune cell checkpoints in disease. Annu Rev Immunol. 2020;38:365-95.
19. Pillai S, Netravali IA, Cariappa A, Mattoo H. Siglecs and immune regulation. Annu Rev Immunol. 2012;30:357-92.
20. Crocker PR, Paulson JC, Varki A. Siglecs and their roles in the immune system. Nat Rev Immunol. 2007;7:255-66.
21. Macauley MS, Crocker PR, Paulson JC. Siglec-mediated regulation of immune cell function in disease. Nat Rev Immunol. 2014;14:653-66.
22. Hudak JE, Canham SM, Bertozzi CR. Glycocalyx engineering reveals a Siglec-based mechanism for NK cell immunoevasion. Nat Chem Biol. 2014;10:69-75.
23. Santegoets KCM, Gielen PR, Büll C, et al. Expression profiling of immune inhibitory Siglecs and their ligands in patients with glioma. Cancer Immunol Immunother. 2019;68:937-49.
24. Silva Z, Rabaça JA, Luz V, et al. New insights into the immunomodulatory potential of sialic acid on monocyte-derived dendritic cells. Cancer Immunol Immunother. 2024;74:9.
25. Silva Z, Soares CO, Barbosa M, Palma AS, Marcelo F, Videira PA. The role of sialoglycans in modulating dendritic cell function and tumour immunity. Semin Immunol. 2024;74-5:101900.
26. Edwards DL, Huang M, Wang TT. Soluble factors and mechanisms regulated by sialylated IgG signaling. Immunol Rev. 2025;330:e70021.
27. Dall'Olio F, Malagolini N, Trinchera M, Chiricolo M. Sialosignaling: sialyltransferases as engines of self-fueling loops in cancer progression. Biochim Biophys Acta. 2014;1840:2752-64.
28. Harduin-lepers. Comprehensive analysis of sialyltransferases in vertebrate genomes. Glycobiol Insights. 2010;2:29-61.
29. Picco G, Julien S, Brockhausen I, et al. Over-expression of ST3Gal-I promotes mammary tumorigenesis. Glycobiology. 2010;20:1241-50.
30. Kvorjak M, Ahmed Y, Miller ML, et al. Cross-talk between colon cells and macrophages increases ST6GALNAC1 and MUC1-sTn expression in ulcerative colitis and colitis-associated colon cancer. Cancer Immunol Res. 2020;8:167-78.
31. Ferreira JA, Videira PA, Lima L, et al. Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours. Mol Oncol. 2013;7:719-31.
32. Carrascal MA, Severino PF, Guadalupe Cabral M, et al. Sialyl Tn-expressing bladder cancer cells induce a tolerogenic phenotype in innate and adaptive immune cells. Mol Oncol. 2014;8:753-65.
33. Jiang Y, Liu Z, Xu F, et al. Aberrant O-glycosylation contributes to tumorigenesis in human colorectal cancer. J Cell Mol Med. 2018;22:4875-85.
34. Zeng J, Mi R, Wang Y, et al. Promoters of human cosmc and T-synthase genes are similar in structure, yet different in epigenetic regulation. J Biol Chem. 2015;290:19018-33.
35. Sun X, Ju T, Cummings RD. Differential expression of Cosmc, T-synthase and mucins in Tn-positive colorectal cancers. BMC Cancer. 2018;18:1-15.
36. Gao T, Du T, Hu X, et al. Cosmc overexpression enhances malignancies in human colon cancer. J Cell Mol Med. 2020;24:362-70.
37. Futamura N, Nakamura S, Tatematsu M, Yamamura Y, Kannagi R, Hirose H. Clinicopathologic significance of sialyl Le xexpression in advanced gastric carcinoma. Br J Cancer. 2000;83:1681-7.
38. Shen L, Luo Z, Wu J, et al. Enhanced expression of α2,3-linked sialic acids promotes gastric cancer cell metastasis and correlates with poor prognosis. Int J Oncol. 2017;50:1201-10.
39. Zhou X, Chi K, Zhang C, Liu Q, Yang G. Sialylation: a cloak for tumors to trick the immune system in the microenvironment. Biology. 2023;12:832.
40. Venkitachalam S, Revoredo L, Varadan V, et al. Biochemical and functional characterization of glycosylation-associated mutational landscapes in colon cancer. Sci Rep. 2016;6:23642.
41. Wang D, Kuzyk V, Madunić K, et al. In-depth analysis of the N-glycome of colorectal cancer cell lines. Int J Mol Sci. 2023;24:4842.
42. Rodrigues JG, Duarte HO, Gomes C, et al. Terminal α2,6-sialylation of epidermal growth factor receptor modulates antibody therapy response of colorectal cancer cells. Cell Oncol. 2021;44:835-50.
43. Mereiter S, Balmaña M, Gomes J, Magalhães A, Reis CA. Glycomic approaches for the discovery of targets in gastrointestinal cancer. Front Oncol. 2016;6:55.
44. Deschepper FM, Zoppi R, Pirro M, et al. L1CAM as an E-selectin ligand in colon cancer. Int J Mol Sci. 2020;21:8286.
45. Wang D, Madunić K, Mayboroda OA, Lageveen-Kammeijer GSM, Wuhrer M. (Sialyl)Lewis antigen expression on glycosphingolipids, N-, and O-glycans in colorectal cancer cell lines is linked to a colon-like differentiation program. Mol Cell Proteomics. 2024;23:100776.
46. Gomes C, Osório H, Pinto MT, Campos D, Oliveira MJ, Reis CA. Expression of ST3GAL4 leads to SLe xexpression and induces c-Met activation and an invasive phenotype in gastric carcinoma cells. PLoS One. 2013;8:e66737.
47. Tian H, Yu JL, Chu X, Guan Q, Liu J, Liu Y. Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression. Front Oncol. 2024;14:1389713.
48. Vázquez-Martín C, Cuevas E, Gil-Martín E, Fernández-Briera A. Correlation analysis between tumor-associated antigen sialyl-Tn expression and ST6GalNAc I activity in human colon adenocarcinoma. Oncology. 2004;67:159-65.
49. Dombek GE, Ore AS, Cheng J, et al. Immunohistochemical analysis of Tn antigen expression in colorectal adenocarcinoma and precursor lesions. BMC Cancer. 2022;22:1281.
50. Yao Y, Kim G, Shafer S, et al. Mucus sialylation determines intestinal host-commensal homeostasis. Cell. 2022;185:1172-88.e28.
51. Lee S, Inzerillo S, Lee GY, Bosire EM, Mahato SK, Song J. Glycan-mediated molecular interactions in bacterial pathogenesis. Trends Microbiol. 2022;30:254-67.
52. Kotlarz D. Mucus sialylation maintains the peace in intestinal host microbe relations. Gastroenterology. 2022;163:527-8.
53. Taniguchi M, Okumura R, Matsuzaki T, et al. Sialylation shapes mucus architecture inhibiting bacterial invasion in the colon. Mucosal Immunol. 2023;16:624-41.
54. Dedola S, Ahmadipour S, de Andrade P, et al. Sialic acids in infection and their potential use in detection and protection against pathogens. RSC Chem Biol. 2024;5:167-88.
55. Arai J, Hayakawa Y, Tateno H, Fujiwara H, Kasuga M, Fujishiro M. The role of gastric mucins and mucin-related glycans in gastric cancers. Cancer Sci. 2024;115:2853-61.
56. Leite-Gomes E, Dias AM, Azevedo CM, et al. Bringing to light the risk of colorectal cancer in inflammatory bowel disease: mucosal glycosylation as a key player. Inflamm Bowel Dis. 2022;28:947-62.
57. Okumura R, Takeda K. The role of the mucosal barrier system in maintaining gut symbiosis to prevent intestinal inflammation. Semin Immunopathol. 2024;47:2.
58. Pothuraju R, Rachagani S, Krishn SR, et al. Molecular implications of MUC5AC-CD44 axis in colorectal cancer progression and chemoresistance. Mol Cancer. 2020;19:37.
60. Ma X, Li M, Wang X, Qi G, Wei L, Zhang D. Sialylation in the gut: from mucosal protection to disease pathogenesis. Carbohydr Polym. 2024;343:122471.
61. Wong SH, Yu J. Gut microbiota in colorectal cancer: mechanisms of action and clinical applications. Nat Rev Gastroenterol Hepatol. 2019;16:690-704.
62. Casasanta MA, Yoo CC, Udayasuryan B, et al. Fusobacterium nucleatum host-cell binding and invasion induces IL-8 and CXCL1 secretion that drives colorectal cancer cell migration. Sci Signal. 2020;13:eaba9157.
63. Duizer C, Salomons M, van Gogh M, et al. Fusobacterium nucleatum upregulates the immune inhibitory receptor PD-L1 in colorectal cancer cells via the activation of ALPK1. Gut Microbes. 2025;17:2458203.
64. Abed J, Emgård JE, Zamir G, et al. Fap2 mediates fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 2016;20:215-25.
65. Caldevilla R, Eiras M, Santos DAR, et al. Advancing non-invasive colorectal cancer screening: exploring the potential of monoclonal antibody L2A5. Int J Mol Sci. 2025;26:3070.
66. Neves M, Azevedo R, Lima L, et al. Exploring sialyl-Tn expression in microfluidic-isolated circulating tumour cells: a novel biomarker and an analytical tool for precision oncology applications. N Biotechnol. 2019;49:77-87.
67. Houvast RD, Vankemmelbeke M, Durrant LG, et al. Targeting glycans and heavily glycosylated proteins for tumor imaging. Cancers. 2020;12:3870.
68. Ibrahim NK, Murray JL. Clinical development of the STn-KLH vaccine (Theratope). Clin Breast Cancer. 2003;3 Suppl 4:S139-43.
69. Holmberg LA, Sandmaier BM. Vaccination with Theratope® (STn-KLH) as treatment for breast cancer. Expert Rev Vaccines. 2004;3:655-63.
70. Sterner E, Flanagan N, Gildersleeve JC. Perspectives on anti-glycan antibodies gleaned from development of a community resource database. ACS Chem Biol. 2016;11:1773-83.
71. Loureiro LR, Feldmann A, Bergmann R, et al. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers. J Exper Clin Cancer Res. 2020;39:77.
72. Loureiro LR, Feldmann A, Bergmann R, et al. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018;8:81.
73. Al-Alem L, Prendergast JM, Clark J, et al. Sialyl-Tn serves as a potential therapeutic target for ovarian cancer. J Ovarian Res. 2024;17:71.
74. Manni M, Läubli H. Targeting glyco-immune checkpoints for cancer therapy. Expert Opin Biol Ther. 2021;21:1063-71.
75. Videira PA, Marcelo F, Grewal RK. Glycosyltransferase inhibitors: a promising strategy to pave a path from laboratory to therapy. Carbohydr Chem. 2017;43:135-58.
